HDAC6 and head and neck squamous cell carcinoma: In one study, a combination of the Wee1 inhibitor adavosertib (AZD1775) and ricolinostat, a selective inhibitor of histone deacetylase 6 (HDAC6), showed synergistic cytotoxicity in HNSCC with TP53 mutations or impaired p53 function caused by HPV infection, possibly by enhancing adavosertib-induced mitotic disaster (120).